touchENDOCRINOLOGY Release: Industry Experts Discuss Recombinant Human Insulins - Clinical Efficacy And Safety In Diabetes Therapy
LONDON, April 21, 2016 /PRNewswire/ --
Wolfgang Landgraf & Juergen Sandow. European Endocrinology, 2016;12(1):12-7 http://doi.org/10.17925/EE.2016.12.01.12
(Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )
Published recently in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Wolfgang Landgraf and Juergen Sandow discusses how insulin replacement therapy is the standard of care for patients with type 1 and advanced type 2 diabetes mellitus. Porcine and bovine pancreatic tissue was the source of the hormone for many years, followed by semisynthetic human insulin obtained by modification of animal insulin. With the development of recombinant DNA technology, recombinant (biosynthetic) human insulin became available in large amounts by biosynthesis in microorganisms (Escherichia coli, yeast) providing reliable supplies of the hormone worldwide at affordable costs. The purity and pharmaceutical quality of recombinant human insulin was demonstrated to be superior to animal and semisynthetic insulin and patients with diabetes could be safely and effectively transferred from animal or semisynthetic human insulin to recombinant human insulin with no change expected in insulin dose. The decision for change remains a clinical objective, follow-up after any change of insulin product is recommended to confirm clinical efficacy. This review provides a summary and retrospective assessment of early clinical studies with recombinant insulins (Insuman®, Humulin®, Novolin®)..
The full peer-reviewed, open-access article is available here:
http://doi.org/10.17925/EE.2016.12.01.12
Disclosure: Wolfgang Landgraf is an employee of Sanofi-Aventis Germany. Juergen Sandow is a consultant to Sanofi Paris.
About touchENDOCRINOLOGY:
touchENDOCRINOLOGY (a division of Touch Medical Media) publishes
European Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
http://www.touchENDOCRINOLOGY.com
For Inquires Please Contact:
Carla Denaro
Managing Editor
managingeditor@touchmedicalmedia.com
Providing practical opinion to support best practice for busy healthcare professionals.
Wolfgang Landgraf & Juergen Sandow. European Endocrinology, 2016;12(1):12-7 http://doi.org/10.17925/EE.2016.12.01.12
(Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )
Published recently in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Wolfgang Landgraf and Juergen Sandow discusses how insulin replacement therapy is the standard of care for patients with type 1 and advanced type 2 diabetes mellitus. Porcine and bovine pancreatic tissue was the source of the hormone for many years, followed by semisynthetic human insulin obtained by modification of animal insulin. With the development of recombinant DNA technology, recombinant (biosynthetic) human insulin became available in large amounts by biosynthesis in microorganisms (Escherichia coli, yeast) providing reliable supplies of the hormone worldwide at affordable costs. The purity and pharmaceutical quality of recombinant human insulin was demonstrated to be superior to animal and semisynthetic insulin and patients with diabetes could be safely and effectively transferred from animal or semisynthetic human insulin to recombinant human insulin with no change expected in insulin dose. The decision for change remains a clinical objective, follow-up after any change of insulin product is recommended to confirm clinical efficacy. This review provides a summary and retrospective assessment of early clinical studies with recombinant insulins (Insuman®, Humulin®, Novolin®)..
The full peer-reviewed, open-access article is available here:
http://doi.org/10.17925/EE.2016.12.01.12
Disclosure: Wolfgang Landgraf is an employee of Sanofi-Aventis Germany. Juergen Sandow is a consultant to Sanofi Paris.
About touchENDOCRINOLOGY:
touchENDOCRINOLOGY (a division of Touch Medical Media) publishes
European Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
http://www.touchENDOCRINOLOGY.com
For Inquires Please Contact:
Carla Denaro
Managing Editor
managingeditor@touchmedicalmedia.com
Providing practical opinion to support best practice for busy healthcare professionals.